These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 8304654

  • 1. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial.
    Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T.
    Ann Intern Med; 1994 Mar 01; 120(5):375-81. PubMed ID: 8304654
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.
    Winston DJ, Wirin D, Shaked A, Busuttil RW.
    Lancet; 1995 Jul 08; 346(8967):69-74. PubMed ID: 7603215
    [Abstract] [Full Text] [Related]

  • 4. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ, Busuttil RW.
    Transplantation; 2003 Jan 27; 75(2):229-33. PubMed ID: 12548129
    [Abstract] [Full Text] [Related]

  • 5. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients.
    Martin M, Mañez R, Linden P, Estores D, Torre-Cisneros J, Kusne S, Ondick L, Ptachcinski R, Irish W, Kisor D.
    Transplantation; 1994 Oct 15; 58(7):779-85. PubMed ID: 7940710
    [Abstract] [Full Text] [Related]

  • 6. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.
    Transplantation; 1998 Dec 27; 66(12):1682-8. PubMed ID: 9884259
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
    Badley AD, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, Walker RC, Patel R, Marshall WF, DeBernardi M, Zetterman R, Steers JL, Paya CV.
    Transplantation; 1997 Jul 15; 64(1):66-73. PubMed ID: 9233703
    [Abstract] [Full Text] [Related]

  • 10. Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients.
    Yango A, Morrissey P, Zanabli A, Beaulieu J, Shemin D, Dworkin L, Monaco A, Gohh R.
    Nephrol Dial Transplant; 2003 Apr 15; 18(4):809-13. PubMed ID: 12637653
    [Abstract] [Full Text] [Related]

  • 11. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
    Bodro M, Sabé N, Lladó L, Baliellas C, Niubó J, Castellote J, Fabregat J, Rafecas A, Carratalà J.
    Liver Transpl; 2012 Sep 15; 18(9):1093-9. PubMed ID: 22532316
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients.
    Reischig T, Opatrný K, Treska V, Mares J, Jindra P, Svecová M.
    Kidney Blood Press Res; 2005 Sep 15; 28(4):218-25. PubMed ID: 16043964
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD.
    Am J Kidney Dis; 2002 May 15; 39(5):1088-95. PubMed ID: 11979354
    [Abstract] [Full Text] [Related]

  • 17. Two strategies for prevention of cytomegalovirus infections after liver transplantation.
    Simon P, Sasse M, Laudi S, Petroff D, Bartels M, Kaisers UX, Bercker S.
    World J Gastroenterol; 2016 Mar 28; 22(12):3412-7. PubMed ID: 27022223
    [Abstract] [Full Text] [Related]

  • 18. Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir.
    Brumble LM, Milstone AP, Loyd JE, Ely EW, Pierson RN, Gautam S, Dummer JS.
    Chest; 2002 Feb 28; 121(2):407-14. PubMed ID: 11834650
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V, Ugur A, Colak D, Saba R, Tezcan G, Kupesiz A, Karadogan I, Gultekin M, Yesilipek A, Undar L.
    Jpn J Infect Dis; 2006 Aug 28; 59(4):216-21. PubMed ID: 16936338
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM, Lake KD, Arenas JD, Fontana RJ.
    Liver Transpl; 2006 Jan 28; 12(1):112-6. PubMed ID: 16382458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.